SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-035160
Filing Date
2022-03-18
Accepted
2022-03-17 18:21:59
Documents
14
Period of Report
2022-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm229544d1_8k.htm   iXBRL 8-K 25006
5 EXHIBIT 99.1 tm229544d1_ex99-1.htm EX-99.1 96927
6 GRAPHIC tm229544d1_ex99-1img001.jpg GRAPHIC 33577
  Complete submission text file 0001104659-22-035160.txt   352701

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20220317.xsd EX-101.SCH 3036
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20220317_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20220317_pre.xml EX-101.PRE 22597
8 EXTRACTED XBRL INSTANCE DOCUMENT tm229544d1_8k_htm.xml XML 3611
Mailing Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027
Business Address 3200 SOUTHWEST FREEWAY SUITE 2500 HOUSTON TX 77027 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

IRS No.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37939 | Film No.: 22750250
SIC: 2834 Pharmaceutical Preparations